Back to top
more

OrthoPediatrics (KIDS)

(Delayed Data from NSDQ)

$25.72 USD

25.72
367,372

-1.77 (-6.44%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $25.84 +0.12 (0.47%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

BSX Gets FDA Nod on INGEVITY+ Pacing Lead in the LBBA: Stock to Gain?

by Zacks Equity Research

Boston Scientific received FDA approval on the expanded indication for INGEVITY+ Pacing Leads. Data demonstrated this lead to be safe and effective for LBBA pacing.

Does OrthoPediatrics (KIDS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in OrthoPediatrics (KIDS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

KIDS Stock Gains From Its New Enabling Technologies Division Launch

by Zacks Equity Research

OrthoPediatrics recently launched its Enabling Technologies division, set to generate sustainable revenue growth and gain access to new markets and specialties beyond orthopedics.

Can HITI Stock Get a Boost From Bricks-and-Mortar Sales in Q3 Earnings?

by Zacks Equity Research

Given High Tide's progress in executing its strategic initiatives, we expect it to report robust Q3 bricks-and-mortar segment sales.

Wall Street Analysts Predict a 31.2% Upside in OrthoPediatrics (KIDS): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 31.2% upside potential for OrthoPediatrics (KIDS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

OrthoPediatrics (KIDS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for OrthoPediatrics (KIDS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 25.81% and 0.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Teleflex (TFX) delivered earnings and revenue surprises of 2.70% and 1.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Avanos Medical (AVNS) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Avanos Medical (AVNS) delivered earnings and revenue surprises of 17.24% and 0.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

OrthoPediatrics (KIDS) Soars 7.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

OrthoPediatrics (KIDS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

CVRx (CVRX) Stock Jumps 33.9%: Will It Continue to Soar?

by Zacks Equity Research

CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

OrthoPediatrics (KIDS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 28.57% and 7.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

OrthoPediatrics (KIDS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

OrthoPediatrics (KIDS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 17.86% and 0.06%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

ReWalk Robotics (LFWD) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

ReWalk (LFWD) delivered earnings and revenue surprises of 61.54% and 4.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

OrthoPediatrics (KIDS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OrthoPediatrics (KIDS) Introduces Unit for Non-Surgical Bracing

by Zacks Equity Research

OrthoPediatrics (KIDS) continues to diversify its non-surgical offerings with the introduction of the DF2 Brace.

Compared to Estimates, OrthoPediatrics (KIDS) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for OrthoPediatrics (KIDS) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Strength Seen in OrthoPediatrics (KIDS): Can Its 8.1% Jump Turn into More Strength?

by Zacks Equity Research

OrthoPediatrics (KIDS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Orthofix (OFIX) Soars 6.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Orthofix (OFIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Compared to Estimates, OrthoPediatrics (KIDS) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 0% and 1.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OrthoPediatrics (KIDS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

OrthoPediatrics (KIDS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.